SBC Medical Group Holdings Inc(SBC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,381 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
SBC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for SBC Medical Group Holdings Inc (SBC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SBC at 51.6/100 on a 32-signal composite quality model, placing it at rank #1,381 of 2,879 stocks — the top half of the AI-ranked universe. SBC scores in the top quartile across balance sheet strength (90.7), profitability (88.6). Areas of concern include free cash flow (18.5) and revenue scale (23.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), SBC Medical Group Holdings Inc reports quarterly revenue of $43.1M, net income of $11.3M, an operating margin of 41.1%. Top institutional holders of SBC by reported 13-F value include BlackRock,, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SBC trades on the Nasdaq exchange and files with the SEC under CIK 1930313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SBC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SBC Medical Group Holdings Inc directly from SEC EDGAR. SBC Medical Group Holdings Inc's 13F Pro composite quality score has ranged between 39 and 57 since 2025, currently 51.6 — a declining long-term trajectory across 10 quarterly and live scoring snapshots.
Revenue
Q1 2026
$43.1M
Net Income
Q1 2026
$11.3M
Free Cash Flow
Q1 2026
$9.1M
Operating Margin
Q1 2026
41.1%
D/E Ratio
Q1 2026
0.16
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+6.1% YoYNet Income
+18.4% YoYOperating Income
-0.5% YoYEPS (Diluted)
+14.3% YoYTotal Assets
+2.8% YoYTotal Debt
+416.2% YoYOp. Cash Flow
-59.4% YoY| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Revenue | $205.4M +6.1% | $193.5M |
| Net Income | $46.6M +18.4% | $39.4M |
| Operating Income | $70.3M -0.5% | $70.7M |
| EPS (Diluted) | $0.48 +14.3% | $0.42 |
| Total Assets | $266.1M +2.8% | $258.8M |
| Total Debt | $6.9M +416.2% | $1.3M |
| Operating Cash Flow | $20.6M -59.4% | $50.7M |
AI Insight: SBC Financial Trends
Revenue stalled near $40–47M range over eight quarters while debt nearly quintupled from $1M to $41M, masking volatile profitability swings.
• Operating cash flow swung from -$21M in Q3 2025 to +$52M in Q4 2025, then +$9M in Q1 2026, showing erratic working capital or timing patterns.
• Net income collapsed from $22M in Q1 2025 to $2M–$14M range across subsequent quarters, indicating margin pressure or one-time benefits in Q1 2025.
• Total debt surged from $1M in Q3 2024 to $41M–$43M in Q4 2025–Q1 2026, while equity grew modestly from $9M to $255M, indicating significant leverage increase.
⚠ Revenue declined 9% from Q4 2024 ($44M) to Q1 2026 ($43M) — no growth trajectory evident over five quarters.
⚠ Operating margin deteriorated from 51% in Q2 2024 to 42% in Q1 2026; Q1 2025's 51% margin appears anomalous amid trend decline.
AI Insight: SBC Ratio Trends
Operating margin rebounded to 41.1% in Q1 2026 after dipping to 32.5% in Q4 2025, but net profit margin volatility signals earnings quality concerns.
• Operating margin improved from 32.5% (Q4 2025) to 41.1% (Q1 2026), returning to mid-range of prior-year levels.
• ROIC stabilized at 23.9% (Q1 2026) after dip to 17.6% (Q4 2025), remaining well above 9.3% (Q4 2024) baseline.
• Leverage remains low at 0.16 D/E (Q1 2026), though up from 0.03 in prior two quarters—still within conservative range.
⚠ Net profit margin collapsed to 5.7% (Q2 2025) from 45.4% (Q1 2025), then recovered to 26.3% (Q1 2026)—high volatility suggests one-offs or operational inconsistency.
⚠ ROE and ROA declined in Q1 2026 (17.7% and 11.7%) versus TTM (16.0% and 10.5%), indicating potential sequential softness.
Get alerted when SBC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SBC Medical Group Holdings Inc including:
Top Institutional Holders of SBC
BlackRock, Inc.
$1.8M419,640 shGEODE CAPITAL MANAGEMENT, LLC
$1.2M295,779 shVANGUARD CAPITAL MANAGEMENT LLC
$569.5K136,239 shNORTHERN TRUST CORP
$381.0K91,139 shVANGUARD PORTFOLIO MANAGEMENT LLC
$265.6K63,547 shVANGUARD FIDUCIARY TRUST CO
$261.1K62,473 shSBI Securities Co., Ltd.
$188.4K45,080 shSTATE STREET CORP
$128.9K30,839 shGOLDMAN SACHS GROUP INC
$104.9K25,087 shMariner, LLC
$100.2K23,960 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.8M | 419,640 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.2M | 295,779 |
| VANGUARD CAPITAL MANAGEMENT LLC | $569.5K | 136,239 |
| NORTHERN TRUST CORP | $381.0K | 91,139 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $265.6K | 63,547 |
| VANGUARD FIDUCIARY TRUST CO | $261.1K | 62,473 |
| SBI Securities Co., Ltd. | $188.4K | 45,080 |
| STATE STREET CORP | $128.9K | 30,839 |
| GOLDMAN SACHS GROUP INC | $104.9K | 25,087 |
| Mariner, LLC | $100.2K | 23,960 |
More Healthcare Companies
View all Healthcare →Put SBC on your watchlist
Track score changes the day SBC Medical Group Holdings Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SBC a good stock to buy?
13F Pro's AI-powered analysis of SBC Medical Group Holdings Inc (SBC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SBC are available on the SBC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SBC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SBC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SBC Medical Group Holdings Inc's investment landscape.